Skip to content

Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19

Evaluation of Pain Symptoms Correlation With Biochemical and Radiological Findings in COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04780555
Enrollment
150
Registered
2021-03-03
Start date
2021-03-01
Completion date
2021-08-01
Last updated
2021-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

pain

Brief summary

The neutrophil-lymphocyte ratio (NLR) used to demonstrate inflammatory status in recent years can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests.

Detailed description

Dysregulation in immune responses has been reported in association with hyperinflammation in COVID-19 patients, NLR has been linked to the severity of the patient's clinical status, and an increase in NLR is reported to be an independent risk factor for in-hospital mortality. Pain is a frequently seen symptom at the onset of viral infections and throughout the course of the disease. Although the pain mechanisms triggered by viral pathogens are not yet entirely understood, pain is thought to arise as a result of direct activation of nociceptor neurons by pathogens and their interaction with molecular ligands. Toll-like receptor 7 (TLR7), a pathogen recognition receptor that plays an important role in immune responses to viruses by binding to viral RNA, is known to be involved in pain development in different RNA virus infections. Park et al. showed that extracellular micro RNAs activate nociceptive neurons via the TLR7 pathway. Although these mechanisms have been demonstrated for different viral infections, the viral pathogenesis leading to pain in COVID-19 is still unclear. The purpose of this study was to investigate the prevalence of headache and muscular pain in patients diagnosed with COVID-19 and to determine the relationship between these symptoms and inflammatory parameters.

Interventions

None listed

Sponsors

Abant Izzet Baysal University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-70 * Diagnosed with COVID-19

Exclusion criteria

* Patients with suspected SARS-CoV-2 infection, with two negative RT-PCR tests, hospitalized in the intensive care unit during inclusion in the study * Musculoskeletal pains in the previous three months, with diseases capable of causing myalgia prior to diagnosis (such as fibromyalgia and inflammatory muscle disease) * Cognitive disorders capable of preventing history-taking and physical examination such as mental disability and dementia, * previous history of headache (migraine, tension type headache)

Design outcomes

Primary

MeasureTime frameDescription
Neutrophil-lymphocyte ratio (NLR)BaselineIt can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests
D-dimerBaselinePeripheral venous blood specimens were collected using standard surgical procedures
FibrinogenBaselinePeripheral venous blood specimens were collected using standard surgical procedures

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026